MediGene and Teva sign agreement to commercialize Veregen in Israel
MediGene AG has signed a license and supply agreement with Teva Pharmaceutical Industries Ltd. for the supply and commercialization of Veregen(TM) in Israel. Teva will also be responsible for registering the product in Israel, and upon successful completion of the regulatory procedures, MediGene is entitled to a milestone payment. In addition, MediGene will receive royalties on future sales of the product. Veregen(TM), for the treatment of genital warts, is MediGene's first internally developed drug. Veregen(TM) is already available on the US market and has obtained marketing authorization in Germany.
Dr. Frank Mathias, Chief Executive Officer of MediGene AG, commented: "Following our European commercialization agreements in Germany, Spain, Portugal, Austria, and Switzerland, we have now concluded our first partnership for the commercialization of Veregen(TM) outside Europe and the US. We are particularly proud to have secured Teva, one of the world's top 20 pharmaceutical companies, for the distribution of Veregen(TM)."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.